1541. REARRANGEMENTS OF THE NPM GENE ARE SELECTIVELY BUT INFREQUENTLY ASSOCIATED WITH ANAPLASTIC LARGE-CELL LYMPHOMA (ALCL)

1542. Leukocytoclastic vasculitis after long-term treatment with sunitinib: a case report

1543. SURVIVAL EFFECT OF ERYTHOPOIETIC AGENTS AND VENOUS THROMBOEMBOLISM (VTE) IN MULTIPLE MYELOMA PATIENTS TREATED WITH LENALIDOMIDE AND HIGH-DOSE DEXAMETHASONE

1544. Hyperphosphorylated Paratarg-7 Is a Frequent Antigenic Target of IgM Paraproteins, Is Dominantly Inherited and Represents a Highly Significant Risk Factor for Monoclonal Gammopathy of Undetermined Significance of the IgM Type (IgM-MGUS) and Waldenstrom's Macroglobulinemia (WM), Allowing for the Identification of Family Members at Risk in Cases of Familial IgM-MGUS and WM.

1545. Superior outcomes associated with complete response: Analysis of the phase III VISTA study of bortezomib plus melphalan--prednisone versus melphalan--prednisone

1546. Quality of Life Improvements for Pomalidomide+ Low-Dose Dexamethasone (POM+ LoDEX) in Relapsed and Refractory MM (RRMM): P-430

1547. Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study

1548. Bone remodeling in patients with relapsed/refractory multiple myeloma who receive lenalidomide-based regimens.

1549. Effect of carfilzomib, lenalidomide, and dexamethasone vs lenalidomide and dexamethasone in patients with relapsed multiple myeloma by line of therapy: interim results from the phase 3 ASPIRE study

1550. Zoledronic acid and survival in patients with high BALP

1551. Non-secretory myeloma: one, two, or more entities?

1552. Antimyosin scintigraphy for detection of cardiac amyloidosis

1553. Evidence-Based Focused Review

1554. Angiogenesis in human cancer: implications in cancer therapy

1555. Primary Therapy of Waldenstro{\~A}{\OE}{\"E}† m's Macroglobulinemia (WM) with Weekly Bortezomib, Low-Dose Dexamethasone and Rituximab (BDR): A Phase II Study of the European Myeloma Network

1556. Inhibition of angiogenesis: common theme for cancer and atheromatosis

1557. Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials

1558. Elotuzumab therapy for relapsed or refractory multiple myeloma

1559. Treatment of Waldenstrom’s macroglobulinemia with thalidomide

1560. Prognostic significance of CA 125, CD44, and epithelial membrane antigen in renal cell carcinoma